Sugi Predict

Sugi Predict / Compounds / SCHEMBL11399760

SCHEMBL11399760

SCHEMBL11399760

O=CNc1ccccc1C(=O)CCC(=O)O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NR4A2 P43354 1/20 0.47
▸ ALDH1A1 P00352 7/20 0.46
▸ HSD17B10 Q99714 3/20 0.46
▸ HPGD P15428 2/20 0.46
▸ CYP2C19 P33261 2/20 0.43
▸ GAA P10253 1/20 0.43
▸ OR51E2 Q9H255 1/20 0.43
▸ ADAM17 P78536 1/20 0.43
▸ RAB9A P51151 3/20 0.42
▸ CYP1A2 P05177 2/20 0.42
▸ SMN1; SMN2 Q16637 2/20 0.42
▸ FFAR1 O14842 1/20 0.42
▸ LMNA P02545 1/20 0.42
▸ HIF1A Q16665 1/20 0.42
▸ RXFP1 Q9HBX9 1/20 0.41
▸ TSHR P16473 2/20 0.40
▸ KDM4E B2RXH2 4/20 0.40
▸ KMT2A Q03164 3/20 0.40
▸ POLB P06746 3/20 0.40
▸ GLA P06280 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1331627 0.86 RXFP1 (0.43) ALDH1A1HSD17B10HPGDOR51E2RAB9A
SCHEMBL18672286 0.83 OR51E2 (0.40) ALDH1A1HSD17B10HPGDOR51E2RAB9A
SCHEMBL3259403 0.81 OR51E2 (0.64) CYP2C19OR51E2CYP1A2RXFP1KDM4E
SCHEMBL28790411 0.81 NR4A2 (0.52) NR4A2ALDH1A1HSD17B10HPGDCYP2C19
SCHEMBL27372856 0.80 PYGL (0.39) ALDH1A1HSD17B10HPGD
SCHEMBL12911463 0.79 RXFP1 (0.43) ALDH1A1HSD17B10HPGDCYP2C19GAA
SCHEMBL29413047 0.78 ALDH1A1 (0.57) ALDH1A1HSD17B10HPGDRAB9ACYP1A2
SCHEMBL501876 0.78 ALDH1A1 (0.57) ALDH1A1HSD17B10HPGDRAB9ACYP1A2
SCHEMBL30852301 0.78 MME (0.40) ALDH1A1HSD17B10HPGDLMNATSHR
SCHEMBL27373092 0.78 MME (0.40) ALDH1A1HSD17B10HPGDLMNATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023123613-A1 BIPOLAR AFFECTIVE DISORDER BIOMARKER AND USE THEREOF 浙江大学 2023-07-06 — — WO claimed
WO-2023082820-A1 MARKER FOR LUNG ADENOCARCINOMA DIAGNOSIS AND APPLICATION THEREOF 上海市第一人民医院 2023-05-19 — — WO claimed
WO-2023082821-A1 SERUM METABOLISM MARKER FOR DIAGNOSING BENIGN AND MALIGNANT PULMONARY NODULES AND USE THEREOF 上海市第一人民医院 2023-05-19 — — WO claimed
CN-114423294-A Coffee replica made from individual components 航行食品股份有限公司 2022-04-29 — — CN claimed
JP-55079366-A — — None — — JP disclosed
WO-2026097395-A1 USE OF IDO1 INHIBITOR ALBIFLORIN OR/AND PAEONIFLORIN IN IMMUNOTHERAPY FOR CANCER COMORBID WITH DEPRESSION 张作光 2026-05-15 — — WO disclosed
US-12551478-B2 Quinoline derivative having indoleamine-2,3-dioxygenase inhibitory activity SHENZHEN CHIPSCREEN BIOSCIENCES CO., LTD. (CN) 2026-02-17 — — US disclosed
WO-2025122766-A1 NEURAL INTERFACE DEVICE SCIENCE CORPORATION (US) 2025-06-12 — — WO disclosed
WO-2025107568-A1 USE OF KYNURENIC ACID IN RESISTING HYPERURICEMIA AND STRUCTURAL ANALOG THEREOF IN PREPARING XOD INHIBITOR 集美大学 2025-05-30 — — WO disclosed
WO-2024213794-A1 USE OF PENTYLAMINE DONORS FOR THE TREATMENT OF AUTOIMMUNE DISORDERS Institut National de la Santé et de la Recherche Médicale (FR) 2024-10-17 — — WO disclosed
EP-3730484-B1 INDOLEAMINE-2,3-DIOXYGENASE INHIBITOR, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF HINOVA PHARMACEUTICALS INC (CN) 2024-02-28 — — EP disclosed
WO-2023185709-A1 MARKER COMBINATION FOR DIAGNOSING ADVANCED COLORECTAL TUMOR, AND APPLICATION THEREOF 武汉迈特维尔医学科技有限公司 2023-10-05 — — WO disclosed
WO-2022078356-A1 HETEROAROMATIC AHR INHIBITOR 山东轩竹医药科技有限公司 2022-04-21 — — WO disclosed
US-10036011-B2 Scavenger compounds for improved sequencing-by-synthesis QIAGEN WALTHAM, INC. (US) 2018-07-31 — — US disclosed
US-10036011-B2 Scavenger compounds for improved sequencing-by-synthesis QIAGEN WALTHAM, INC. (US) 2018-07-31 — — US disclosed
WO-2017139415-A2 SCAVENGER COMPOUNDS FOR IMPROVED SEQUENCING-BY-SYNTHESIS QIAGEN WALTHAM, INC. (US) 2017-08-17 — — WO disclosed
US-20170233725-A1 Scavenger Compounds for Improved Sequencing-by-Synthesis IsoPlexis Corporation 2017-08-17 — — US disclosed
US-20170233725-A1 Scavenger Compounds for Improved Sequencing-by-Synthesis IsoPlexis Corporation 2017-08-17 — — US disclosed
US-20150216845-A1 IPA AS A THERAPEUTIC AGENT, AS A PROTECTIVE AGENT, AND AS A BIOMARKER OF DISEASE RISK COUNTERPOINT HEALTH SOLUTIONS INC (US) 2015-08-06 — — US disclosed
JP-S5579366-A PREPARATION OF 2-AMINOINDOLENINE ASAHI CHEM IND CO LTD 1980-06-14 — — JP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12551478-B2 Quinoline derivative having indoleamine-2,3-dioxygenase inhibitory activity IDO2, IDO1, HDAC2 NR4A2 911/4885ALDH1A1 1949/4885HSD17B10 1168/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.